Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4

Annals of Saudi Medicine

Volumn 29, Issue 1, 2009, Pages 4-14

  Al Ashgar, Hamad ^a   Helmy, Ahmed ^a,b   Khan, Mohamed Q ^a   Al Kahtani, Khalid ^a   Al Quaiz, Mohammed ^a   Rezeig, Mohammed ^a   Kagevi, Ingvar ^a   Alshehri, Abdullah ^a   Al Kalbani, Abdullah ^a   Al Swat, Khalid ^a   Dahab, Salim ^a   Elkum, Naser ^a   Al Fadda, Mohammed ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Assiut University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; RELAPSE; RETROSPECTIVE STUDY; SAUDI ARABIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD; VIRUS STRAIN; WEIGHT REDUCTION;

EID: 60149090711     PISSN: 02564947     EISSN: 13199226     Source Type: Journal    
DOI: 10.4103/0256-4947.51816     Document Type: Article

References (61)

1. Lauer GM, Walker BD. Hepatitis C virus infection. New Engl J Med 2001;345:41-52.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatol. 2002;36(Suppl):35-46.
3. NIH Consensus Statement on Management of Hepatitis. NIH Consens Sci Statements. 2002;19:1-46.
4. a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep. 26; 347(13):975-82.
5. a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. Mar 2;140(5):346-55.
6. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU. DITTO-HCV Study Group. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 2005 Aug;43(2):250-7.
7. Dienstag JL, McHutchison JG. American Gastroenterological Association Technical Review on the management of hepatitis C. Gastroenterol. 2006:130:231-64.
8. Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, Kumada H. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2005 Jan;75(1):27-34.
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon _-2b plus ribavirin compared with interferon _-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65.
10. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother. 2004;53:15-18.
11. Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol. 2003;84:2333-41.
12. Chamberlain RW, Adams N, Saeed AA, Simmonds P, Elliott RM. Complete nucleotide sequence of a type hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol. 1997;78:1341-7.
13. Matera G, Lamberti A, Quirino A, Focà D, Giancotti A, Barreca GS, Guadagnino V, Liberto MC. Changes in the prevalence of hepatitis C virus (HCV) genotype in Calabria, Southern Italy. Diagn Microbiol Infect Dis. 2002 Mar;42(3):169-73.
14. Schröter M, Zöllner B, Schäfer P, Reimer A, Müller M, Laufs R, Feucht HH. Epidemiological dynamics of hepatitis C virus among 7 German individuals: new subtypes on the advance. J Clin Microbiol. 2002 May;40(5):1866-8.
15. van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, Rezza G, Broers B, Robertson JR, Brettle RP, McMenamin J, Prins M, Cochrane A, Simmonds P, Coutinho RA, Bruisten S. European and Italian Seroconverter Studies. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis. Jan 15;189(2):292-302.
16. al-Faleh FZ, Ramia S, Arif M, Ayoola EA, al-Rashed RS, al-Jeffry M, Hossain A, el-Hazmi M. Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: a community-based study. Ann Trop Med Parasitol. 1995 Aug;89(4):431-7.
17. al-Faleh FZ, Ayoola EA, al-Jeffry M, al-Rashed R, al-Mofarreh M, Arif M, Ramia S, al-Karawi M, al-Shabrawy M. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: a community-based study. Hepatol. 1991 Aug;14(2):215-8.
18. Al-Ahdal MN, Rezeig MA, Kessie G. Genotyping of hepatitis C virus isolates from Saudi patients by analysis of sequences from PCR-amplified core region of the virus genome. Ann Saudi Med. 1997;17:601-4.
19. Osoba AO. Hepatitis C virus Genotype in Saudi Arabia. Saudi Med J. 2002;23:7-12.
20. Fakeeh M, Zaki AM. Hepatitis C. Prevalence and common genotype among ethic groups in Jeddah, Saudi Arabia. Am J Trop Med Hyg. 1999;61:889-92.
21. Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol. 1999;58:44-8.
22. a: impact of bilharziasis and fibrosis stage. World J Gastroenterol. 2006 Sep 2;12():5692-8.
23. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A. Response of hepatitis C genotype-4 naive patients 24 to weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol. 2005 Nov;100(11):2447-52.
24. el-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, Shawky S. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):472-5.
25. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005 Jun;54(6):858-66.
26. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, Al-Ahdal MN, Mayet I, Khan MQ, Kessie G. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int. 2004 Dec;24(6):568-74.
27. Al-Faleh FZ, Aljumah A, Rezeig M, Al-Kanawi, Al-Otaibi M, Alahdal M, Al-Humayed S, Mayet I, Al-Juhani M, Al-Karawi M, George K, Sbeih F. Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J Viral Hepat. 2000 Jul;7(4):287-91.
28. al-Faleh FZ, Sbeih F, al-Karawi M, al-Mofleh IA, al-Rashed RS, Ayoola A, al-Amri S, Mayet I, al-Habbal TM, al-Omair A, al-Sohaibani MO, Abdullah AO, Mohamed SA, el-Sheikh MA. Treatment of chronic hepatitis C genotype with alpha-interferon in Saudi Arabia: a multicenter study. Hepatogastroenterology. 1998 Mar-Apr;45(20):488-91.
29. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R, Al-Nakib B. Peginterferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol. Sep;99(9):1733-7.
30. Al-Traif I, Handoo FA, Al-Jumah A, Al-Nasser M. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients. Saudi Med J. 2004;25:1935-8.
31. Koshy A, Madda JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol. 2002;35:82-5.
32. Bruno S, Crosignani A, Pinzello GB. Hepatitis C virus genotype 4 and response to combination therapy with interferon-alpha2b plus ribavirin. Ann Intern Med. 2000;133:922-3.
33. Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype is associated with a poor response to interferon-alpha. Ann Intern Med. 2000;132:845-6.
34. Sherman M, Marinos G, Sedarati F. Infection with hepatitis C virus genotype is associated with a poor response to interferon-alpha. Ann Intern Med. 2001;135:927-8.
35. a and ribavirin. Ann Intern Med. 2004; 140:72-3.
36. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype. Aliment Pharmacol Ther. 2004;20:931-8.
37. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatol. 1994 Jul;20(1 Pt 1):15-20.
38. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 1993 Jun;74(Pt 6):1093-102.
39. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat. 2000;7:250-7.
40. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat. 2001;8:1-18.
41. Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther. 2007;25:1153-62.
42. a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterol. 2004 Apr;126(4):1015-23; discussion 947.
43. Mathew A, Peiffer LP, Rhoades K, McGarrity T. Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci. 2006;51:1956-61.
44. Hua LL, Lee SC. Distinct patterns of stimulus-inducible chemokine mRNA accumulation in human fetal astrocytes and microglia. Glia. 2000;30:74-81.
45. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol. 2003 Sep;74(3):360-9.
46. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 2005 Aug 15;106(4):1175-82.
47. Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut. 2006 Mar;55(3):374-9.
48. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K. DITTO-HCV Study Group. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatol. 2004 Dec;44(6):1617-25.
49. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F. Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat. 2007 Jul;14(7):460-7.
50. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. Virahep-C Study Group. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007 Aug;81(15):8211-24.
51. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterol. 2005 Mar;128(3):636-41.
52. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR. HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C:results from the HALT-C Trial. J Hepatol. 2005 Sep;43(3):434-41.
53. Zechini B, Pasquazzi C, Aceti A. Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol. 2004;16:891-6.
54. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol. 2000;95:1545-50.
55. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL. Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatol. 2007 Mar;45(3):579-87.
56. Arif A, Levine RA, Sanderson SO, Bank L, Velu RP, Shah A, Mahl TC, Gregory DH. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci. 2003 Jul;48(7):1425-30.
57. Metwally MA, Zein CO, Zein NN. Regression of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C treated with interferon-based therapy. Gastroenterol. 2003;124:1561.
58. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci. 1998;43:2573-6.
59. Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, Castillo I, Weiland O, Nevens F, Hansen BE, Schalm SW. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004 Oct; 53(10):1504-8
60. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatol. 2007 Dec;46(6):1732-40.
61. a and ribavirin in patients with chronic hepatitis C: A tertiary care center experience. Saudi J Gastroenterol. 2008;14(2):58-65.